Table 1.

Characteristics of tamoxifen and raloxifene users and matched non-users

	Tamoxifen				Raloxifene
	Users		Non-users		Users		Non-users
	N	%	N	%	N	%	N	%
Total	96	100%	953	100%	432	100%	4307	100%
Index age
<55	64	67%	633	66%	162	38%	1617	39%
55–59	12	13%	120	13%	150	35%	1499	34%
60–64	14	15%	140	15%	84	19%	840	19%
65+	6	6%	60	6%	36	8%	351	8%
Mean (SD)	52	(7)	52	(7)	56	(6)	56	(6)
Menopausal status at index age
Premenopausal	56	59%	497	52%	80	19%	1106	27%
Postmenopausal	39	41%	451	48%	351	81%	3199	73%
Missing	1		5		1		2
Race/ethnicity
Non-Hispanic White	83	86%	839	88%	415	96%	3870	90%
Other	13	14% a	114	12% b	17	4% c	437	10% d
Education
High school or less	7	7%	122	13%	51	12%	588	14%
Some college	29	30%	291	31%	117	27%	1451	34%
Bachelor’s degree or higher	60	63%	540	57%	264	61%	2268	52%
Hysterectomy before index age
No	82	86%	743	79%	303	70%	2928	69%
Yes	13	14%	198	21%	129	30%	1358	31%
Missing	1		12		0		21
Osteoporosis or osteopenia diagnosis before index age
No	75	78%	782	82%	271	63%	3451	80%
Yes	21	22%	171	18%	161	37%	856	20%
Number of first degree relatives with breast cancer
0 e	2	2%	29	3%	5	1%	88	2%
1	57	59%	704	74%	208	48%	3202	74%
2+	37	39%	220	23%	219	51%	1017	24%
BCRAT score (%) f
<1.67	12	13%	189	20%	12	3%	219	6%
1.67–2.99	39	41%	448	47%	118	27%	2168	50%
3.00–5.99	38	40%	272	29%	227	53%	1559	36%
≥6.00	7	7%	44	5%	75	17%	361	8%
Mean (SD)	3.2	(1.7)	2.8	(1.5)	4.2	(1.9)	3.4	(1.7)
Years since chemoprevention initiation
0.2–4.9	56	58%			43	10%
5–9.9	38	40%			146	34%
10+	2	2%			243	56%
Median (IQR)	4	(3, 6)			11	(8, 14)

^aIncludes 9% non-Hispanic Black, 2% Hispanic, 2% other

^bIncludes 6% non-Hispanic Black, 3% Hispanic, 3% other

^cIncludes 1% non-Hispanic Black, 2% Hispanic, 1% other

^dIncludes 5% non-Hispanic Black, 3% Hispanic, 2% other

^eHalf-sister only

^fInformation on history of a breast biopsy with atypical hyperplasia, a component of the BCRAT, was categorized as ‘unknown’ in the risk calculation for all women